Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer
Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer
Blog Article
Abstract Background Tumor resistance represents a major challenge in the current oncology landscape.Asparagine endopeptidase (AEP) overexpression correlates with worse prognosis and reduced overall survival in most human solid tumors.However, the underlying mechanisms of the connection between AEP and reduced overall survival in cancer patients remain unclear.
Methods High-throughput proteomics, cellular and molecular biology approaches and clinical data from breast cancer (BC) patients were used to identify novel, biologically relevant AEP targets.Immunoblotting and qPCR analyses were used to quantify protein and mRNA levels.Flow cytometry, confocal microscopy, chemical inhibitors, siRNA- and shRNA-silencing and DNA repair assays were used as functional assays.
In-silico analyses using the TCGA BC dataset and immunofluorescence assays in an independent cohort of Mirror invasive ductal (ID) BC patients were used to validate the clinical relevance of our findings.Results Here we showed a dual role for AEP in genomic stability and radiotherapy resistance in BC patients by suppressing ATR and PPP1R10 levels.Reduced ATR and PPP1R10 levels were found in BC patients expressing high AEP levels and correlated with worst prognosis.
Mechanistically, AEP suppresses ATR levels, reducing DNA damage-induced cell death, and PPP1R10 levels, promoting Chek1/P53 cell cycle checkpoint activation, allowing BC cells to efficiently Cobra Kai repair DNA.Functional studies revealed AEP-deficiency results in genomic instability, increased DNA damage signaling, reduced Chek1/P53 activation, impaired DNA repair and cell death, with phosphatase inhibitors restoring the DNA damage response in AEP-deficient BC cells.Furthermore, AEP inhibition sensitized BC cells to the chemotherapeutic reagents cisplatin and etoposide.
Immunofluorescence assays in an independent cohort of IDBC patients showed increased AEP levels in ductal cells.These analyses showed that higher AEP levels in radioresistant IDBC patients resulted in ATR nuclear eviction, revealing AEPhigh/ATRlow protein levels as an efficient predictive biomarker for the stratification of radioresistant patients.Conclusion The newly identified AEP/ATR/PPP1R10 axis plays a dual role in genomic stability and radiotherapy resistance in BC.
Our work provides new clues to the underlying mechanisms of tumor resistance and strong evidence validating the AEP/ATR axis as a novel predictive biomarker and therapeutic target for the stratification and treatment of radioresistant BC patients.